PMID- 23151275
OWN - NLM
STAT- MEDLINE
DCOM- 20130903
LR  - 20221207
IS  - 1471-2369 (Electronic)
IS  - 1471-2369 (Linking)
VI  - 13
DP  - 2012 Nov 14
TI  - Relationships between serum MCP-1 and subclinical kidney disease: African 
      American-Diabetes Heart Study.
PG  - 148
LID - 10.1186/1471-2369-13-148 [doi]
AB  - AB BACKGROUND: Monocyte chemoattractant protein-1 (MCP-1) plays important roles 
      in kidney disease susceptibility and atherogenesis in experimental models. 
      Relationships between serum MCP-1 concentration and early nephropathy and 
      subclinical cardiovascular disease (CVD) were assessed in African Americans (AAs) 
      with type 2 diabetes (T2D). METHODS: Serum MCP-1 concentration, urine 
      albumin:creatinine ratio (ACR), estimated glomerular filtration rate (eGFR), and 
      atherosclerotic calcified plaque (CP) in the coronary and carotid arteries and 
      infrarenal aorta were measured in 479 unrelated AAs with T2D. Generalized linear 
      models were fitted to test for associations between MCP-1 and urine ACR, eGFR, 
      and CP. RESULTS: Participants were 57% female, with mean +/- SD (median) age 55.6 +/- 
      9.5 (55.0) years, diabetes duration 10.3 +/- 8.2 (8.0) years, urine ACR 149.7 +/- 
      566.7 (14.0) mg/g, CKD-EPI eGFR 92.4 +/- 23.3 (92.0) ml/min/1.73 m(2), MCP-1 262.9 
      +/- 239.1 (224.4) pg/ml, coronary artery CP 280.1 +/- 633.8 (13.5), carotid artery CP 
      47.1 +/- 132.9 (0), and aorta CP 1616.0 +/- 2864.0 (319.0). Adjusting for age, sex, 
      smoking, HbA1c, BMI, and LDL, serum MCP-1 was positively associated with 
      albuminuria (parameter estimate 0.0021, P=0.04) and negatively associated with 
      eGFR (parameter estimate -0.0003, P=0.001). MCP-1 remained associated with eGFR 
      after adjustment for urine ACR. MCP-1 levels did not correlate with the extent of 
      CP in any vascular bed, HbA1c or diabetes duration, but were positively 
      associated with BMI. No interaction between BMI and MCP-1 was detected on 
      nephropathy outcomes. CONCLUSIONS: Serum MCP-1 levels are associated with eGFR 
      and albuminuria in AAs with T2D. MCP-1 was not associated with subclinical CVD in 
      this population. Inflammation appears to play important roles in development 
      and/or progression of kidney disease in AAs.
FAU - Murea, Mariana
AU  - Murea M
AD  - Department of Internal Medicine/Nephrology, Wake Forest School of Medicine, 
      Medical Center Boulevard, Winston-Salem, NC, 27157-1053, USA. 
      mmurea@wakehealth.edu.
FAU - Register, Thomas C
AU  - Register TC
FAU - Divers, Jasmin
AU  - Divers J
FAU - Bowden, Donald W
AU  - Bowden DW
FAU - Carr, J Jeffrey
AU  - Carr JJ
FAU - Hightower, Caresse R
AU  - Hightower CR
FAU - Xu, Jianzhao
AU  - Xu J
FAU - Smith, S Carrie
AU  - Smith SC
FAU - Hruska, Keith A
AU  - Hruska KA
FAU - Langefeld, Carl D
AU  - Langefeld CD
FAU - Freedman, Barry I
AU  - Freedman BI
LA  - eng
GR  - R01 DK071891/DK/NIDDK NIH HHS/United States
GR  - M01 RR07122/RR/NCRR NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20121114
PL  - England
TA  - BMC Nephrol
JT  - BMC nephrology
JID - 100967793
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
SB  - IM
MH  - *Black or African American/ethnology
MH  - Aged
MH  - Albuminuria/*blood/*diagnosis/ethnology
MH  - Biomarkers/blood
MH  - Chemokine CCL2/*blood
MH  - Cohort Studies
MH  - Diabetes Mellitus, Type 2/*blood/diagnosis/ethnology
MH  - Female
MH  - Humans
MH  - Kidney Diseases/*blood/diagnosis/ethnology
MH  - Male
MH  - Middle Aged
MH  - Plaque, Atherosclerotic/blood/diagnosis/ethnology
PMC - PMC3534523
EDAT- 2012/11/16 06:00
MHDA- 2013/09/04 06:00
PMCR- 2012/11/14
CRDT- 2012/11/16 06:00
PHST- 2012/05/24 00:00 [received]
PHST- 2012/10/18 00:00 [accepted]
PHST- 2012/11/16 06:00 [entrez]
PHST- 2012/11/16 06:00 [pubmed]
PHST- 2013/09/04 06:00 [medline]
PHST- 2012/11/14 00:00 [pmc-release]
AID - 1471-2369-13-148 [pii]
AID - 10.1186/1471-2369-13-148 [doi]
PST - epublish
SO  - BMC Nephrol. 2012 Nov 14;13:148. doi: 10.1186/1471-2369-13-148.